RIXATHON is a biosimilar medication primarily used in the treatment of certain types of cancers, including non-Hodgkin lymphoma and chronic lymphocytic leukemia, as well as autoimmune diseases such as rheumatoid arthritis. It is designed to mimic the effects of the original biologic drug, rituximab, offering a more cost-effective alternative while maintaining similar safety and efficacy profiles. RIXATHON works by targeting and attaching to the CD20 protein found on the surface of B cells (a type of white blood cell), which plays a key role in both cancerous conditions and autoimmune diseases. By doing so, it helps to destroy these cells, aiding in the management of the conditions it is prescribed for. As with any medication, the use of RIXATHON should be under the guidance of a healthcare professional, with consideration given to its indications, dosing, and potential side effects.